Ophthalmology Times: strikingly low glaucoma adherence

Glaucoma treatment sounds simple on paper — lower eye pressure, protect the optic nerve, save vision. But the everyday version is messy. Patients forget drops, miss the eye, stop because of irritation, or just get tired of doing the same thing forever. That gap between prescription and real life is the whole story here. Ophthalmology Times put that problem front and center in its discussion of glaucoma implants. The basic argument is blunt: daily drops work only if people actually use them, and a lot of people do not. That is why sustained-release implants like Glaukos’ iDose TR are getting framed less as a fancy add-on and more as a practical answer to a very old failure point. (ophthalmologytimes.com) ### Why are glaucoma drops so hard to stick with? Because glaucoma is usually silent until damage is advanced. Patients do not feel the disease getting worse day to day, but they do feel the hassle of bottles, schedules, cost, blurry vision, red eyes, and the awkward mechanics of getting a drop into the ey(ophthalmologytimes.com)ing nonadherence across studies anywhere from roughly 30% to 80%. (pmc.ncbi.nlm.nih.gov) ### What did Ophthalmology Times actually highlight? The piece leaned on clinician experience — patients confusing bottles, missing doses, and struggling with chronic therapy — and called the adherence numbers “strikingly low.” It also tied that directly to the rise of interventional glaucoma care, where the goal is to get pressure-lowering treatment in(pmc.ncbi.nlm.nih.gov)or years. (ophthalmologytimes.com) ### So what is iDose TR? It is a tiny intracameral implant — meaning it sits inside the front part of the eye — that slowly releases travoprost, a prostaglandin used to lower intraocular pressure in open-angle glaucoma or ocular hypertension. The device contains 75 mcg of drug in a titanium reservoir and i(ophthalmologytimes.com)he medicine is placed where it needs to work. (glaukos.com) ### What changed recently? The important new wrinkle is not just that iDose TR exists. It is that the label was updated in January 2026 to include instructions for re-administration, after Ophthalmology Times had already covered earlier positive platform updates and 36-month follow-up data. That matters because a one-time implant is useful, but a therapy t(glaukos.com) (ophthalmologytimes.com) ### Does this replace drops for everyone? No — and that is the catch. Implants are procedures, not simple prescriptions. They come with insertion technique, follow-up, and safety considerations, including device location and patient selection. The label also carries warnings and contrain(ophthalmologytimes.com)ld, the tradeoff can make a lot of sense. (glaukos.com) ### Why does the adherence angle matter so much? Because glaucoma damage is permanent. If pressure control slips for months or years, the vision loss does not come back. That makes adherence different from a lot of other medication problems — the missed doses may feel harmless in the moment, but the consequence can be irreversible. Sustained-release treatm(glaukos.com)s and technique failure from the equation. (ophthalmologytimes.com) ### Where is this heading? The field is clearly moving toward “procedural pharmaceuticals” — drug delivery built into office-based or surgical glaucoma care. Ophthalmology Times has been explicit about that framing, covering both bimatoprost and travoprost implants as ways to reduce dependence on self-admi(ophthalmologytimes.com) drops to delivering medication directly. (ophthalmologytimes.com) ### Bottom line The real news is not just a new glaucoma device. It is the industry admitting, pretty openly, that the old model — daily drops forever — breaks down for a lot of patients, and implants are being built to solve exactly that problem.